[生物书合集].Advances.in.Clinical.TBiostatisti

[生物书合集].Advances.in.Clinical.TBiostatisti

Info iconThis preview shows page 1. Sign up to view the full content.

View Full Document Right Arrow Icon
3. A loss function quantifying the total cost associated with the administration of any permissible dose level. The loss will be expressed through a function L defined on S ± Q , where S is the set of dose levels available for use in the trial. Hence, L ( x , N ) denotes the loss incurred by treating a patient at dose level x 2 S when N 2 Q obtains. Through an application of Bayes’ theorem the dose-toxicity model and prior distribution can be used to derive the posterior distribution of N given D k . Hence, we obtain a function C k defined on the parametric space Q such that m I C k ð u Þ d u is the conditional probability that N is contained in I p Q given the data available after k patients have been observed. We can then compute EL k ð x Þ¼ Z H L ð x ; u Þ C k ð u Þ d u representing the posterior expected loss associated with dose x 2 S after observation of k patients. When a phase I trial is designed according to strict Bayesian decision-theoretic principles, dose escalation proceeds by
Background image of page 1
This is the end of the preview. Sign up to access the rest of the document.

This note was uploaded on 06/13/2011 for the course PHYSICS 101 taught by Professor Shu during the Spring '11 term at FIU.

Ask a homework question - tutors are online